Published in:
01-10-2002 | Original Research Article
UK Department of Health Guidance on Prescribing for Impotence Following the Introduction of Sildenafil
Potential to Contain Costs in the Average Health Authority District
Published in: PharmacoEconomics | Issue 12/2002
Login to get accessAbstract
Objectives: To evaluate the effectiveness at containing service costs of the UK’s Department of Health (DoH) guidance on prescribing for impotence implemented after the introduction of sildenafil and taking effect from 1 July 1999.
Design: A pragmatic economic analysis of the impact of the DoH guidance on specialist-care activity and costs and primary-care prescribing costs from the perspective of the UK National Health Service. Primary-care prescribing costs and specialist-care activity and cost data were collected for 12-month periods before and after the introduction of the guidance.
Setting: Portsmouth and South East Hampshire Health Authority.
Results: Specialist-care activity and associated costs fell by 70% in the first year following the introduction of the DoH guidance while primary-care prescribing costs doubled. The overall cost for providing impotence services in Portsmouth and South East Hampshire in 1999–2000 was £232 619, and is similar to the cost incurred in 1998–1999 of £225 108 (uplifted to 1999–2000 values).
Conclusions: The DoH guidance on prescribing for impotence has effectively reduced specialist-care activity and costs in Portsmouth and South East Hampshire. It offers the potential to allow the overall costs of impotence services in the district to be contained even with the use of higher cost drugs, such as sildenafil.